Clinical trials: Second Line Treatment
Cartilage Injury
Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft
Patient with IKDC score < 65, pretreated with mosaicplasty or ACI ( with matrix or not) within > 18 months, with one or two osteochondral lesions are recruited to have treated osteochondral allografts in mosaicplasty.
- Trial name
- ODPHOENIX2 (NCT02430558)
- Testing
- OD-PHOENIX
- Volunteers
- 10 people
- Sponsor
- TBF Genie Tissulaire
HIV
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
The purpose of this study is to determine the proportion of subjects with HIV-1 RNA < 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an…
- Trial name
- SUPPRESS (NCT01605084)
- Testing
- Atazanavir, Darunavir, Ritonavir
- Where
- 14 sites in United States
- Sponsor
- Bristol-Myers Squibb
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Advanced Colorectal Cancer, Colorectal Cancer
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with…
- Trial name
- NCT00498407
- Testing
- CP-4055
- Where
- 4 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Clavis Pharma
Carcinoma, Non-Small-Cell Lung
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
- Trial name
- NCT00059722
- Testing
- ZD6474, ZD1839
- Where
- 48 sites in United States, Argentina and 4 more
- Volunteers
- 160 people
- Sponsor
- Genzyme, a Sanofi Company
Small Cell Lung Cancer
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of…
- Trial name
- NCT02038647
- Testing
- Alisertib, Paclitaxel
- Where
- 61 sites in United States, Belgium and 8 more
- Volunteers
- 178 people
- Sponsor
- Millennium Pharmaceuticals, Inc.